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OBJECTIVE: Oral lichen planus (OLP) is chronic
inflammatory disease of the oral mucosa, presenting
in various clinical forms. The etiology of OLP is still
unknown but mounting evidence points to the
immunologic basis of this disorder.
Aim: Our study was undertaken to quantify the
salivary levels of pro-inflammatory tumor necrosis
factor-alpha (TNF-a) in the reticular and the erosive/
atrophic forms of OLP, compared with age-matched
healthy control volunteers.
Subjects and methods: Whole saliva from 40 patients
with active lesions of OLP, as well as from 20 healthy
persons, was investigated for the presence of TNF-a
by enzyme immunoassay.
Results: Salivary TNF-a levels were significantlly
increased in patients with OLP in comparison with
healthy subjects. The presence of TNF-a showed
positive correlation to clinical forms of OLP, being
significantly higher in the erosive/atrophic type than
in the reticular type of disease.
Conclusion: Saliva provides an ideal medium for the
detection of pro-inflammatory markers of the oral
cavity. In patients with OLP, TNF-a levels in saliva are
elevated, correlating with the severity of illness.
Salivary TNF-a analysis may be a useful diagnostic
tool and a potential prognostic marker in OLP.
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Introduction
Oral lichen planus (OLP) is a relatively common
mucocutaneous disease of unknown etiology.
1 It is
thought to affect about 0.5/2% of the world popula-
tion, more often females at a mean age of onset in
the fourth decade, although younger adults and
children may be affected too. The cause of OLP is
still not known, but cell-mediated immune dysfunc-
tion is implicated in the complex ethiopathogenesis
of this disease. The immunologic process results in
vacuolar degeneration, lysis and, ultimately, liquefac-
tion of the basal cells. The large amount of cytokines
released by affected keratinocytes and the associated
inflammatory elements plays a key role in the
selective recruitment of the T lymphocytes. T-cell-
dominated infiltrate in the subepithelial region,
which characterizes OLP, induces further release of
chemokines and cytokines belonging to either the
Th1 or Th2 groups.
2 Such a mixed cytokine profile
has been demonstrated by Simark-Mattsson et al.,
who found elevated concentrations of interleukin
(IL)-2, IL-6 and IL-10, as well as tumor necrosis factor
(TNF)-a and transforming growth factor-b within the
subepithelial infiltrate in OLP patients.
3
TNF-a is a multifunctional cytokine that plays a
prominentroleinimmuneandhostdefenseresponses
to infection,
4 stimulates angiogenesis,
5 influences
tissue remodeling,
6 and takes part in the regulation
of cell proliferation and differentiation. It has been
identified as an important mediator of cancer devel-
opment
7 and a powerful activator not only of apopto-
tic, but also anti-apoptotic signaling cascades.
8 Data
collected during the past decade have pointed to
TNF-a as a key cytokine in cutaneous lichen planus,
9
as well as in OLP.
10 High serum levels of TNF-a were
detectedinallpatientswithOLPincomparisonwithits
hardly detectable levels in control subjects.
11 Simulta-
neouslywiththeexpressionofotherpro-inflammatory
and anti-inflammatory cytokines mRNAs, all the OLP
lesions have been shown to contain cells with mRNA
for TNF-a.
12
In this report we present data characterizing the
patternofTNF-aproductioninwholesalivaofpatients
with OLP. We wanted to evaluate whether the salivary
concentations of TNF-a were changed and whether
they correlate with different clinical forms of OLP.
Subjects and methods
Patients
Forty patients with active lesions of OLP (20 with
clinical diagnosis of the reticular form, and 20 with
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131the erosive/atrophic form of disease) were included
in this study. The clinical examination was performed
according to the standard clinical criteria. Lesions
were described as reticular if mainly lacelike hyper-
keratotic patterns were presented. Lesions were
described as erosive/atrophic if they exhibited
erythematous change with few or aggressive ulcers.
Clinical diagnosis of OLP was verified by an inci-
sional biopsy. Twenty age-matched healthy volun-
teers served as a control group.
Saliva collection and cytokine assay
After informent consent had been obtained and
medical, denture and social histories collected, each
individual expectorated 10 ml of unstimulated whole
saliva into a sterile centrifuge tube. The saliva was
centrifuged for 2 min at 9880/g and the clarified
supernatant was filtered through a 0.45 mm low
protein binding membrane, separated into 0.5 ml
aliquots and frozen at /808C until use. Concentra-
tions of TNF-a were determined using the human
TNF-a ELISA kit purchased from SIGMA Immuno
Chemicals (St Louis, MO, USA). The assay was
performed according to the manufacturer’s instruc-
tions, and the results are expressed in pg/ml. The
detection limit for TNF-a was 4.4 pg/ml, respectively.
The test was performed in duplicate and repeated
three times. The protein content was the results
expressed in pg/ml.
Statistical analysis
Data are presented as median values, interquartile
range (IQR) and on a logarithmic scale. The results
obtained were compared using the non-parametric
Wilcox test. A statistically significant difference was
defined at pB/0.05.
Results
Biopsed OLP tissues were stained with hematoxylin
and eosin (HE staining) to evaluate the characteristic
histopathological features of OLP. In each case the
clinical diagnosis was confirmed by a biopsy with a
histologic appearance that included a band-like,
mainly lymphocytic, infiltrate in the connective tissue
adjacent to the epithelial basement membrane, liqui-
faction degeneration of the basement membrane, and
destruction of basal keratinocytes. The levels of
TNF-a were measured in the whole saliva of healthy
volunteers, as well as in patients with OLP, reticular
form or erosive/atrophic form, and are presented as
the median (IQR) on a logarithmic scale in Fig. 1.
Sufficient quantities of TNF-a (1.39 pg/ml,
IQR/1.27/1.64) were present in all saliva samples
obtained from healthy subjects. Salivary levels of
TNF-a were elevated in all patients presenting
symptomatic OLP. The median values (2.83 pg/ml,
IQR/2.27/2.98) of TNF-a in saliva of the patients
with the reticular form, as well as the erosive/
atrophic form (3.08 pg/ml, IQR/3.01/3.19), of the
disease were significantly (p B/0.0001) higher in
comparison with the values obtained from con-
trol subjects. A statistically significant difference
(pB/0.001) was also demonstrated between the
two, reticular versus erosive/atrophic, types of OLP,
being more pronounced in the erosive/atrophic form,
correlating with the severity of this malady.
Discussion
OLP is a persisting inflammatory keratotic disorder of
oral mucous membranes. It may affect any part of the
oral cavity, but the buccal mucosa, gingiva and
tongue are the predominant sites. The disease occurs
in a number of different clinical forms.
1 However,
reticular and erosive/atrophic forms are the most
FIG. 1. The levels of TNF-a in the saliva samples from healthy volunteers and patients with the reticular form or the erosive/
atrophic form of OLP. Data represent the median log10 cytokine content (IQR) per milliliter of saliva derived from 20 subjects.
Signiﬁcance: healthy volunteers versus reticular and erosive/atrophic forms (pB/0.0001), and reticular form versus erosive/
atrophic form of OLP (pB/0.001).
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malady has not been fully elucidated, but it is
generally accepted that immunological mecchanisms
present the basis in the ethiopathogenesis of OLP.
2
The immunologic process results in vacuolar degen-
eration of the germinative epithelial layer and
destruction of the basal cells. Histochemical studies
have identified T lymphocytes as a predominant
infiltrating population. The major subset associated
with the basal layer and responsible for the damage
of keratinocytes is CD8
 cytotoxic T cells.
13 T
lymphocytes that dominate the subepithelial region
are major contributors of cytokines too. In addition,
epidermal keratinocytes also appear to participate in
producing cytokines in inflammatory lesions, perpe-
tuating the condition by inducing adhesion molecule
expression, playing a role in the selective recruitment
of the T-cell-dominated infiltrate and inducing further
cytokine release.
2 Despite that in OLP lesions mixed
cytokines are simultaneously generated belonging to
both Th1 and Th2 profiles, TNF-a has been impli-
cated to have a key role in the initiation and
progression of the disease. Elevated concentrations
of TNF-a were detected in the sera
11 and locally in
the oral mucosal tissue of the OLP patients. Augmen-
ted mRNA levels detected in tissues by PCR seem to
correlate with our results (i.e. with local protein
synthesis). We found a significantly higher amount
of TNF-a in all saliva samples obtained from patients
with active OLP lesions in comparison with the
healthy controls. Moreover, our data showed that
salivary TNF-a concentrations varied in different
clinical types of OLP, being particularly elevated in
the case of the erosive/atrophic form of the disease. It
is obvious that enhanced TNF-a production in saliva
reflects clinical changes and correlates with the
severity of OLP. A permanent or prolonged presence
of high TNF-a amounts in saliva may contribute to
malignant transformation of OLP lesions. It is known
that TNF-a has a role in carcinogenesis, as well as that
the erosive/atrophic form of OLP has a greater rate of
malignant evolution in comparison with the reticular
form of the disease,
14 stressing the prognostic poten-
tial of TNF-a in saliva. As a diagnostic fluid, saliva is
underused. It offers distinctive advantages over
serum because it can be collected non-invasively by
individuals with modest training. Furthermore, saliva
analysis demonstrated comparable values of various
biochemical and immunological parameters with
those that are routinely evaluated in blood.
15 Saliva
has more diagnostic value that is generally appre-
ciated and has promise as an aid in the diagnosis of
systemic and esspecially oral pathologies.
OLP occupies an important place in dental practice
because of the morbidity associated with oral lesions
and their propensity for malignant development. Our
data suggest an important role of high concentrations
of TNF-a in perpetuation of the pathogenetical events
in OLP. Inhibiting TNF-a activities in this disease may
provide therapeutic benefits but more experimental
and clinical studies are required for possible efficacy
of drugs that can interfere with excess TNF-a. Based
on the presence of TNF-a in whole saliva we think
that saliva analysis is a useful, worthwile tool in the
diagnosis and follow-up of OLP, particularly in
patients with erosive/atrophic affections of oral
mucosa.
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